Gate2Brain
  • Home
  • Company
  • Team
  • Technology
  • Pipeline-Proof of Concept
  • Investors
  • News & Media
  • Contact
  • Menu Menu

G2B receives funding to accelerate its transfer to the market and society

News

Gate2Brain, a spin-off of Sant Joan de Déu (SJD), Institute for Research in Biomedicine (IRB) Barcelona and University of Barcelona (UB) will develop a new drug using a shuttle peptide that crosses the blood-brain barrier (BBB) to improve treatments for pediatric brain cancer.

.  has been awarded 300,000 euro funding by the 2021 CaixaResearch Consolidate call. With this award, “la Caixa” Foundation will help Gate2Brain to advance its technology and reach the society. The ultimate goal of this project is to enhance the health and quality of life of children with brain tumors such as diffuse intrinsic pontine glioma (DIPG).

DIPG is the most severe type of brain cancer, and it affects approximately two children per million yearly. Currently, there is no cure or effective treatment for this disease, and the median survival after diagnosis is only 8-11 months.

Although certain drugs show potent anticancer activity against DIPG in vitro, all of them have failed in clinical trials. The likely reason for such failure is that they cannot cross the BBB to reach the tumor. The BBB is a protective cellular barrier that allows only certain molecules from the circulating blood to get into the brain, and it prevents pathogens and other substances, including most anticancer medicines, from entering.

The spin-off Gate2Brain has designed a shuttle peptide that can carry drugs across the BBB to treat DIPG and other brain diseases. The company aims to carry out the preclinical validation of the new drug G2B-002. Gate2Brain shuttles can be adapted to a wide range of molecules, showing enormous potential to treat various brain diseases.

“Humankind has always dreamt of reaching the outer space and also the inside of our brain. At Gate2Brain, we dream of helping drugs enter the brain and thus of being able to treat pediatric cancers such as DIPG.”

Gate2Brain was launched in 2020, founded by Dr. Meritxell Teixidó, CEO of the company, with the participation of SJD Barcelona Children’s Hospital, SJD Research Foundation, IRB Barcelona and UB. The Mind the Gap Program of the Botín Foundation invested €500,000 and endorsed the project through the incorporation of one expert entrepreneur as advisor. Shortly after its launching, the company received additional support from the BStartup Health Program of Banco Sabadell (€100,000). Located at the Barcelona Science Park, Gate2Brain collaborates actively with the Pediatric Cancer Program at the Institut de Recerca Sant Joan de Déu.

GATE2BRAIN AND ANOTHER THREE INNOVATIVE BIOMEDICAL PROJECTS ARE STRENGTHENED BY THE SUPPORT FROM “LA CAIXA” FOUNDATION

In addition to the Gate2Brain project, other awardees include one project to develop synthetic cells for viral infections, a technological approach to overcome resistance and recurrence of cancer stem cells, and intelligent glasses to correct serious eye defects.

Beyond the funding of up to €300,000 per project, the awardees receive support in technology transfer, funding tools and negotiations, and mentorship by experts that help define personalized development and commercialization plans.

The 2021 CaixaResearch Consolidate call supported these projects to promote the transfer of knowledge and technologies in the field of biomedicine and health and to provide support for the creation of new research-based companies. The call remains open throughout the year to ensure that applicant projects receive adequate funding in a timely manner.

Source: https://www.irsjd.org/en/news-and-events/news/836/gate2brain-receives-funding-from-la-caixa-foundation-to-accelerate-its-transfer-to-the-market-and-society

 

January 13, 2022/by noticias
Tags: BBB, Biotech, DIGP, IRB, SJD
Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on LinkedIn
  • Share by Mail
https://gate2brain.com/wp-content/uploads/2022/01/Captura-de-pantalla-2022-01-13-a-las-13.32.08-1.png 1195 2448 noticias https://gate2brain.com/wp-content/uploads/2020/12/Logo-Gate1Brain500pxGrueso.png noticias2022-01-13 13:39:072022-01-17 17:27:58G2B receives funding to accelerate its transfer to the market and society
You might also like
Biotech New Frontiers Award 2022Gate2Brain G2B awarded with Biotech New Frontiers 2022
medicines beyond barriersG2B Medicines beyond barriers
Many drugs do not reach the brain and Gate2Brain technology helps to overcome that bottleneck
‘Tractor’ proteins that carry drugs to the brain as therapy for incurable pediatric cancer
Gate2Brain will be attending in Basel, Switzerland, the Investment Readiness Series, a @Biocat initiative co-organized by the Delegation of the Government of Catalonia in Switzerland, The aim of the meeting is to put the best projects - from companies and/or research organizations - in contact with investors, business angels, venture capitalists and leading Swiss companies. Gate2Brain will be attending The Investment Readiness Series
Nadia Calviño, First Vice President of the Government and Minister of Economic Affairs visits Gate2BrainSJD Nadia Calviño, First Vice President of the Government visits Gate2Brain
CaixaImpuls Gate2Brain as alumni at Caixa Impulse Validate
EITHealth Catapult 2022eithealth Gate2Brain semifinalist of EITHealth’s Catapult 2022

CATEGORIES

  • Clipping
  • Events
  • News
  • Podcast
  • Press releases
  • Publications
  • Videos

Events

  • 📢 On December 13h, Gate2Brain will be participating together with Maribel Berges (AFFIRMA BIOTECH SL), Sven Dr. Mulfinger (Dana_positive maternal health), and Diana Ballart (The Smart Lollipop) in the i4kids Closing Event 2022, sharing achievements and failures of entrepreneurs in #pediatric and maternal #healthcare.i4kidsi4kids Closing Event 2022December 7, 2022 - 12:37
  • WomenStartupAwards, in the "Inspiration" category.WomeninTechSpainFinalist of Women Startup AwardsNovember 15, 2022 - 17:46
  • GORDON CONFERENCESgate2brainGordon Research ConferencesNovember 3, 2022 - 11:41
  • Gate2Brain's retreat 2022Gate2BrainGate2Brain’s retreat 2022October 24, 2022 - 19:27
  • BIO EUROPE 2022GATE2BRAINGate2Brain at BIO-EUROPE 2022September 22, 2022 - 13:39

SOCIAL

  • linkedin
  • youtube

RSS RSS Ciencia

  • What will the d·Health Barcelona Part Time program clinical immersion be like? January 24, 2023 biocat
  • Good start to the year in investment and advances in projects at science facilities January 24, 2023 biocat
  • AseBio and Biocat present BIOSPAIN 2023 in Barcelona to over 200 people from the sector January 16, 2023 biocat
  • 2022: Healthcare research and innovation are strategic priorities for Catalonia December 23, 2022 biocat
  • 5th edition of CRAASH Barcelona program comes to an end December 21, 2022 biocat
  • Registration now open for presentation of 2022 BioRegion Report December 20, 2022 biocat
  • Open Innovation Forum consolidates role resolving innovation challenges in BioRegion December 20, 2022 biocat
  • AseBio and Biocat to present BIOSPAIN 2023 in Barcelona at public event open to whole ecosystem December 12, 2022 biocat
Gate2Brain

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We use a radically innovative peptide-based patented technology.

Where to find us

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain
info@gate2brain.com

Social

  • linkedin
  • youtube
© Copyright –Edisenius
  • Privacy Policy
  • Legal Notice
  • Cookie Policy
Four innovative biomedical projects boosted by the Fundació “la Caix... Cuatro proyectos biomédicos innovadores reciben el impulso de la Fundación ”la Caixa” para acelerar su llegada al mercado y a la sociedadFundació La Caixa ¿Cómo transportar fármacos al cerebro para tratar patologías?La Vanguardia How to transport drugs to the brain to treat pathologies?
Scroll to top
Manage Cookie Consent
This Website uses proprietary and third-party cookies to improve services and facilitate browsing. You can obtain further information about the cookies this site uses and how to limit them in the
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}